BE A HERO: VOLUNTEER FOR CLINICAL TRIAL OF COVID-19 THERAPIES


Study Title:
 ACTIV-2 Outpatient Monoclonal Antibodies and other Therapies (ACTG A5401).

Study Description:
ACTIV-2 is a randomized, blinded, controlled adaptive platform that allows promising investigational agents to be added and removed over the course of the study, in order to efficiently test a variety of new agents against placebo within the same trial infrastructure.

ACTIV-2 will evaluate the safety and efficacy of investigational agents to treat adults who have COVID-19 illness but do not require hospitalization. The study will also enable researchers to assess the correlation between changes in viral shedding and clinical outcomes, leading to a better understanding of whether effective medications can reduce or halt the transmission of SARS-CoV-2 (the virus that causes COVID-19) to others.

Why is this study being done?
To rapidly and efficiently evaluate multiple potential therapeutics for COVID-19 in an outpatient setting.

Who can join?
  • Ambulatory Adult (18 years or older)
  • Active SARS-CoV-2 infection <7 days prior to Entry
  • At least one typical COVID-19 symptom for <10 days prior to Entry, plus one the following symptoms present within 48 hours of entry: 
    • Fever or feeling feverish, cough, shortness of breath at rest or with activity, sore throat, body or muscle pain, fatigue, headache, chills
Duration of study: 28 days of intensive follow-up, followed by limited follow-up through 24 weeks.

Study Investigators: The AIDS Clinical Trials Group (ACTG), the world’s largest and longest established HIV research network.

Participating Clinical Research Sites (CRS):
  • Harbor University of California Los Angeles Center CRS - Torrance, California
  • Massachusetts General Hospital (MGH) CRS - Boston, Massachusetts
  • Northwestern University CRS - Chicago, Illinois
  • Ohio State University CRS - Columbus, Ohio
  • Rush University CRS - Chicago, Illinois
  • The Ponce de Leon Center CRS - Atlanta, Georgia
  • University of California, Los Angeles CARE Center CRS - Los Angeles, California
  • University of California, San Diego AntiViral Research Center CRS - San Diego, California
  • University of Colorado Denver ATN CRS - Denver, Colorado
  • University of North Carolina Global HIV Prevention and Treatment CTU - Chapel Hill, North Carolina
  • University of Pittsburgh CRS - Pittsburgh, Pennsylvania
  • University of Washington AIDS Clinical Trials Unit CRS - Seattle, Washington
  • Vanderbilt Therapeutics (VT) CRS - Nashville, Tennessee
  • Washington University Therapeutics (WT) CRS - St. Louis, Missouri
  • Weill Cornell Uptown CRS - New York, New York
For more information, click here: https://www.activ-2.org/en

Comments

Popular posts from this blog

YOU CAN’T LOVE NIGERIA & WANT BOLA TINUBU AS ITS PRESIDENT

THE PATRON OF PREBENDALISM EYES ASO ROCK (PART II)

DON’T BE A DATA POINT ON THE COVID DEATH CHART